Cargando…

Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity

Visceral adipose tissue (VAT) metabolic fingerprints differ according to body mass index (BMI) and glycemic status. Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon are gut-associated hormones that play an important role in regulating energy and glucos...

Descripción completa

Detalles Bibliográficos
Autores principales: Morais, Tiago, Seabra, Alexandre L., Patrício, Bárbara G., Carrageta, David F., Guimarães, Marta, Nora, Mário, Oliveira, Pedro F., Alves, Marco G., Monteiro, Mariana P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224016/
https://www.ncbi.nlm.nih.gov/pubmed/37233628
http://dx.doi.org/10.3390/metabo13050587
_version_ 1785050077147955200
author Morais, Tiago
Seabra, Alexandre L.
Patrício, Bárbara G.
Carrageta, David F.
Guimarães, Marta
Nora, Mário
Oliveira, Pedro F.
Alves, Marco G.
Monteiro, Mariana P.
author_facet Morais, Tiago
Seabra, Alexandre L.
Patrício, Bárbara G.
Carrageta, David F.
Guimarães, Marta
Nora, Mário
Oliveira, Pedro F.
Alves, Marco G.
Monteiro, Mariana P.
author_sort Morais, Tiago
collection PubMed
description Visceral adipose tissue (VAT) metabolic fingerprints differ according to body mass index (BMI) and glycemic status. Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon are gut-associated hormones that play an important role in regulating energy and glucose homeostasis, although their metabolic actions in VAT are still poorly characterized. Our aim was to assess whether GLP-1, GIP and glucagon influence the VAT metabolite profile. To achieve this goal, VAT harvested during elective surgical procedures from individuals (N = 19) with different BMIs and glycemic statuses was stimulated with GLP-1, GIP or glucagon, and culture media was analyzed using proton nuclear magnetic resonance. In the VAT of individuals with obesity and prediabetes, GLP-1 shifted its metabolic profile by increasing alanine and lactate production while also decreasing isoleucine consumption, whereas GIP and glucagon decreased lactate and alanine production and increased pyruvate consumption. In summary, GLP-1, GIP and glucagon were shown to distinctively modulate the VAT metabolic profile depending on the subject’s BMI and glycemic status. In VAT from patients with obesity and prediabetes, these hormones induced metabolic shifts toward gluconeogenesis suppression and oxidative phosphorylation enhancement, suggesting an overall improvement in AT mitochondrial function.
format Online
Article
Text
id pubmed-10224016
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102240162023-05-28 Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity Morais, Tiago Seabra, Alexandre L. Patrício, Bárbara G. Carrageta, David F. Guimarães, Marta Nora, Mário Oliveira, Pedro F. Alves, Marco G. Monteiro, Mariana P. Metabolites Article Visceral adipose tissue (VAT) metabolic fingerprints differ according to body mass index (BMI) and glycemic status. Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon are gut-associated hormones that play an important role in regulating energy and glucose homeostasis, although their metabolic actions in VAT are still poorly characterized. Our aim was to assess whether GLP-1, GIP and glucagon influence the VAT metabolite profile. To achieve this goal, VAT harvested during elective surgical procedures from individuals (N = 19) with different BMIs and glycemic statuses was stimulated with GLP-1, GIP or glucagon, and culture media was analyzed using proton nuclear magnetic resonance. In the VAT of individuals with obesity and prediabetes, GLP-1 shifted its metabolic profile by increasing alanine and lactate production while also decreasing isoleucine consumption, whereas GIP and glucagon decreased lactate and alanine production and increased pyruvate consumption. In summary, GLP-1, GIP and glucagon were shown to distinctively modulate the VAT metabolic profile depending on the subject’s BMI and glycemic status. In VAT from patients with obesity and prediabetes, these hormones induced metabolic shifts toward gluconeogenesis suppression and oxidative phosphorylation enhancement, suggesting an overall improvement in AT mitochondrial function. MDPI 2023-04-24 /pmc/articles/PMC10224016/ /pubmed/37233628 http://dx.doi.org/10.3390/metabo13050587 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Morais, Tiago
Seabra, Alexandre L.
Patrício, Bárbara G.
Carrageta, David F.
Guimarães, Marta
Nora, Mário
Oliveira, Pedro F.
Alves, Marco G.
Monteiro, Mariana P.
Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
title Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
title_full Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
title_fullStr Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
title_full_unstemmed Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
title_short Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
title_sort dysglycemia shapes visceral adipose tissue’s response to gip, glp-1 and glucagon in individuals with obesity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224016/
https://www.ncbi.nlm.nih.gov/pubmed/37233628
http://dx.doi.org/10.3390/metabo13050587
work_keys_str_mv AT moraistiago dysglycemiashapesvisceraladiposetissuesresponsetogipglp1andglucagoninindividualswithobesity
AT seabraalexandrel dysglycemiashapesvisceraladiposetissuesresponsetogipglp1andglucagoninindividualswithobesity
AT patriciobarbarag dysglycemiashapesvisceraladiposetissuesresponsetogipglp1andglucagoninindividualswithobesity
AT carragetadavidf dysglycemiashapesvisceraladiposetissuesresponsetogipglp1andglucagoninindividualswithobesity
AT guimaraesmarta dysglycemiashapesvisceraladiposetissuesresponsetogipglp1andglucagoninindividualswithobesity
AT noramario dysglycemiashapesvisceraladiposetissuesresponsetogipglp1andglucagoninindividualswithobesity
AT oliveirapedrof dysglycemiashapesvisceraladiposetissuesresponsetogipglp1andglucagoninindividualswithobesity
AT alvesmarcog dysglycemiashapesvisceraladiposetissuesresponsetogipglp1andglucagoninindividualswithobesity
AT monteiromarianap dysglycemiashapesvisceraladiposetissuesresponsetogipglp1andglucagoninindividualswithobesity